Page data last changed: . Chemistry registry snapshot: . Registry refreshes and identity assessments are separate from scientific content review.
A venom-derived cyclic heptapeptide that blocks platelet aggregation.
Also known as: Integrilin
Part of the Foundational & therapeutic peptides cluster
Overview
Eptifibatide is a synthetic cyclic heptapeptide derived from a disintegrin in pygmy rattlesnake venom. It reversibly blocks the platelet glycoprotein IIb/IIIa receptor, the final common step of platelet aggregation, and it is an approved antiplatelet therapeutic for acute coronary syndrome and coronary intervention. Content here is educational only.
Source & context
Biological / chemical source: Synthetic cyclic heptapeptide from snake-venom disintegrin
Primary research or clinical context: Approved for acute coronary syndrome and percutaneous coronary intervention
Disintegrin mimicry
Snake-venom disintegrins interrupt clotting by mimicking the RGD/KGD motif that binds platelet integrins. Eptifibatide captures this KGD-mimetic motif in a stable cyclic peptide, a well-known example of venom-inspired drug design.
Final-step blockade
Because glycoprotein IIb/IIIa engagement with fibrinogen is the last step in platelet cross-linking, blocking it prevents aggregation regardless of the activating stimulus. Its reversible binding is often contrasted with irreversible antiplatelet agents in cardiology teaching.
Structure & chemistry
Molecular identity & reference confidence
Source-supported reference
Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.
- Molecular form
- Eptifibatide (source record; form not independently established)
- Species
- Not established by this molecular identity audit
- Termini (N / C)
- Not specified / Not specified
Average reference mass
Reference policy updated: 2026-10-05
- IUPHAR/BPS source snapshot · 2026-10-01
- PubChem molecular record · 2026-10-01
- Molecular formula
- C35H49N11O9S2
- Average reference mass
- ≈ 832
- Status
- Approved medicine in at least one jurisdiction (IUPHAR record)
- PubChem CID: 448812
- IUPHAR ligand: 6585
- ChEMBL: CHEMBL1174
- DrugBank: DB00063
- CAS RN: 188627-80-7
- UNII: NA8320J834
Chemistry values: PubChem, IUPHAR/BPS Guide to Pharmacology · fetched 2026-10-01.
Clinical development snapshot
ClinicalTrials.gov lists 35 registered studies with “Eptifibatide” as an intervention (snapshot 2026-09-06). A registry footprint is not evidence of efficacy or approval.
| NCT | Title | Phase | Status | Updated |
|---|---|---|---|---|
| NCT07347626 | Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis | Phase 3 | not yet recruiting | 2026-01-16 |
| NCT03735979 | Multi-arm Optimization of Stroke Thrombolysis | Phase 3 | completed | 2025-02-07 |
| NCT00089895 | EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syn | Phase 3 | completed | 2024-05-17 |
| NCT05415150 | Platelet Function in Patients With Ischemic Stroke Treated With Anti-thrombotic or Thrombolytic | Phase 2 | unknown | 2022-06-10 |
| NCT01991366 | Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevatio | — | withdrawn | 2021-07-02 |
| NCT01522417 | Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention | Phase 2 | completed | 2021-05-13 |
Eptifibatide — reconstitution calculator
Enter how much peptide is in the vial and how much diluent (e.g. bacteriostatic water) is added. The tool returns the resulting solution concentration — and, for any amount you type, the volume it corresponds to. This is educational arithmetic, not a dosing recommendation.
Reference form: Eptifibatide (source record; form not independently established)Average reference mass: 832 Da
Enter an amount to see the volume it corresponds to.
Educational concentration mathematics only. This tool does not recommend a dose, amount, or protocol, and nothing here is medical advice. Many peptides are not authorized by Health Canada for human use — see our reconstitution and bacteriostatic-water guides for context.
FAQ about Eptifibatide
What is Eptifibatide?+
Eptifibatide is a synthetic cyclic heptapeptide derived from a disintegrin in pygmy rattlesnake venom. It reversibly blocks the platelet glycoprotein IIb/IIIa receptor, the final common step of platelet aggregation, and it is an approved antiplatelet therapeutic for acute coronary syndrome and coronary intervention. Content here is educational only.
What Canadian product status is recorded for Eptifibatide?+
Canadian product status for Eptifibatide has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.
What is the typical length of Eptifibatide?+
Eptifibatide is commonly described as approximately 7 amino acids (GPIIb/IIIa inhibitor).
Related peptides
References & further reading
- 1.Adeoye et al. (2024). Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke. N Engl J Med
- 2.Roy et al. (2025). Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial. Neurology
- 3.Rines et al. (2025). Intravenous Argatroban or Eptifibatide in Patients Undergoing Mechanical Thrombectomy: A Subgroup Analysis of the MOST Randomized Clinical Trial. JAMA Neurol
- 4.Waldron et al. (2017). Bleeding risk associated with eptifibatide (Integrilin) bridging in thoracic surgery patients. J Thromb Thrombolysis
- 5.Parakh et al. (2009). Eptifibatide overdose. Int J Cardiol
- 6.Phillips et al. (1997). Clinical pharmacology of eptifibatide. Am J Cardiol
- 7.Scarborough (1999). Development of eptifibatide. Am Heart J
- 8.Holmvang et al. (2001). [Eptifibatide (Integrilin)]. Ugeskr Laeger
- 9.PubChem — compound summary for Eptifibatide (CID 448812)
- 10.Wikipedia — Eptifibatide